Logo

Mylan and Biocon's Semglee Receives EU Approval for Patients with Diabetes

Share this

Mylan and Biocon's Semglee Receives EU Approval for Patients with Diabetes

Shots:

  • The approval is based on CHMP (EMA) recommendation- reviewed by EU for diabetic patients
  • In 2009- Mylan and Biocon globally collaborated to jointly develop multiple generic biologic compounds
  • Semglee is a prefilled 100unit/ml 3ml disposable pen- approved in Australia by TGA and in EU including Norway- Iceland and Liechtenstein for patients with diabetes with its expected launch in H2’18

Ref: Mylan | Image: Medical News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions